http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Zynerba Pharmaceuticals Announces Planned Retirement of Suzanne Hanlon and Appoints Albert P. Parker as Chief Legal Officer
-
Zynerba Pharmaceuticals to Present at the SVB Leerink Global Healthcare Conference
-
Zynerba Pharmaceuticals to Present at the SVB Leerink Global Healthcare Conference
-
Zynerba Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference
-
Zynerba Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference
-
Zynerba Pharma (ZYNE) Announces Clinical Development Updates for FXS, ASD, 22q and DEE
-
Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE
-
Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE
-
Zynerba Pharmaceuticals Announces Presentation at The BRAIN Foundation Synchrony 2021 Symposium
-
Zynerba Pharmaceuticals Announces Presentation at The BRAIN Foundation Synchrony 2021 Symposium
-
Zynerba Pharma (ZYNE) Awarded New Zygel Patent in EU
-
Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel™
-
Zynerba Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October
-
Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October
-
Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
-
Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
-
Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conference & Exhibition
-
Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conference & Exhibition
-
Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
-
Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
-
Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
-
Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
-
Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel™ in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phen
-
Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel™ in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phen
-
Zynerba Pharma (ZYNE) Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Netwo
-
Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Net
-
Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Net
-
Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
-
Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
-
Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021
-
Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021
-
Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference
-
Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference
-
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference
-
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference
-
Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting
-
Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting
-
Zynerba Pharma (ZYNE) Presents Sleep Data from Study of Zygel in Children and Adolescents with Both DEE and ASD at Associated Professional Sleep Societies SLEEP 2021 Annual
-
Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel™ in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder (ASD) at the As
-
Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel™ in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder (ASD) at the As
-
Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting
-
Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting
-
Zynerba Pharmaceuticals Announces Acceptance of Poster at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting
-
Zynerba Pharmaceuticals Announces Acceptance of Poster at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting
-
Zynerba Pharma (ZYNE) Announces Presentation of Efficacy and Safety Findings in Children and Adolescents with Autism Spectrum Disorder and Related Disorders at ASCP
-
Zynerba Pharmaceuticals Announces Presentation of Efficacy and Safety Findings in Children and Adolescents with Autism Spectrum Disorder (ASD) and Related Disorders at the 2021 American Society of Cli

